United Therapeutics Corporation To Report Fourth Quarter And Annual 2018 Financial Results Before The Market Opens On Wednesday, February 27, 2019
The teleconference is accessible by dialing 1-877-351-5881, with international callers dialing 1-970-315-0533. A rebroadcast of the teleconference will be available for one week and can be accessed by dialing 1-855-859-2056, with international callers dialing 1-404-537-3406, and using access code: 1595239.
This teleconference is also being webcast and can be accessed via
Through our wholly-owned subsidiary, Lung Biotechnology PBC, we are focused on addressing the acute national shortage of transplantable lungs and other organs with a variety of technologies that either delay the need for such organs or expand the supply. Lung Biotechnology is the first public benefit corporation subsidiary of a public biotechnology or pharmaceutical company.
View original content:http://www.prnewswire.com/news-releases/united-therapeutics-corporation-to-report-fourth-quarter-and-annual-2018-financial-results-before-the-market-opens-on-wednesday-february-27-2019-300798448.html
James Edgemond, (301) 608-9292, email@example.com